Limits...
Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival.

Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z - Oncotarget (2015)

Bottom Line: Patient survival rates at 1, 3 and 5 years significantly improved from P1 to P2.Over the last 10 years, the patient survival had a significant increase which was mainly a result of the optimal therapeutic selections according to disease stages in this center.However, the proportion of patients diagnosed at early stages of HCC remained low and did not increase, a result calling for implementing surveillance system for at risk patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, 710061 Shaanxi, China.

ABSTRACT

Background: Hepatocellular carcinoma (HCC) is among the most common and lethal cancers worldwide, especially in China.

Methods: We retrospectively analyzed data from patients who were diagnosed and treated HCC between 2002 and 2011 in a large hospital in northwest China and compared the data between periods 2002-2006 (P1) and 2007-2011 (P2).

Results: 2045 patients were included in analysis. The HCC stages at diagnosis according to the Barcelona clinic liver cancer staging system had no significant change. Treatment options of liver transplantation, transcatheter arterial chemoembolization and other therapy decreased while percutaneous local ablation and supportive care increased from P1 to P2. Options of surgical resection and systematic therapy had no significant change. Patient survival rates at 1, 3 and 5 years significantly improved from P1 to P2. The treatments with increasing option trend had a higher magnitude of survival increase and vise versa.

Conclusion: Over the last 10 years, the patient survival had a significant increase which was mainly a result of the optimal therapeutic selections according to disease stages in this center. However, the proportion of patients diagnosed at early stages of HCC remained low and did not increase, a result calling for implementing surveillance system for at risk patients.

Show MeSH

Related in: MedlinePlus

Cumulative survival of the hepatocellular carcinoma (HCC) patients by treatment in the two considered periods 2002–2006 (P1) and 2007–2011 (P2)(A) Liver transplantation. (B) Surgical resection. (C) Transcatheter arterial chemoembolization (TACE). (D) Percutaneous local ablation. (E) Systematic therapy. (F) Supportive care. (G) Other therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4414202&req=5

Figure 4: Cumulative survival of the hepatocellular carcinoma (HCC) patients by treatment in the two considered periods 2002–2006 (P1) and 2007–2011 (P2)(A) Liver transplantation. (B) Surgical resection. (C) Transcatheter arterial chemoembolization (TACE). (D) Percutaneous local ablation. (E) Systematic therapy. (F) Supportive care. (G) Other therapy.

Mentions: A significant survival increasing trend can also be seen in almost each treatment, except other therapy, from P1 to P2 (p = 0.043, p < 0.001, p < 0.001, p = 0.002, p = 0.002, p = 0.005 and p = 0.097 for liver transplantation, resection, TACE, percutaneous local ablation, systematic therapy, supportive care and the other therapy, respectively, Figure 4A–4G).


Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival.

Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z - Oncotarget (2015)

Cumulative survival of the hepatocellular carcinoma (HCC) patients by treatment in the two considered periods 2002–2006 (P1) and 2007–2011 (P2)(A) Liver transplantation. (B) Surgical resection. (C) Transcatheter arterial chemoembolization (TACE). (D) Percutaneous local ablation. (E) Systematic therapy. (F) Supportive care. (G) Other therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4414202&req=5

Figure 4: Cumulative survival of the hepatocellular carcinoma (HCC) patients by treatment in the two considered periods 2002–2006 (P1) and 2007–2011 (P2)(A) Liver transplantation. (B) Surgical resection. (C) Transcatheter arterial chemoembolization (TACE). (D) Percutaneous local ablation. (E) Systematic therapy. (F) Supportive care. (G) Other therapy.
Mentions: A significant survival increasing trend can also be seen in almost each treatment, except other therapy, from P1 to P2 (p = 0.043, p < 0.001, p < 0.001, p = 0.002, p = 0.002, p = 0.005 and p = 0.097 for liver transplantation, resection, TACE, percutaneous local ablation, systematic therapy, supportive care and the other therapy, respectively, Figure 4A–4G).

Bottom Line: Patient survival rates at 1, 3 and 5 years significantly improved from P1 to P2.Over the last 10 years, the patient survival had a significant increase which was mainly a result of the optimal therapeutic selections according to disease stages in this center.However, the proportion of patients diagnosed at early stages of HCC remained low and did not increase, a result calling for implementing surveillance system for at risk patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, 710061 Shaanxi, China.

ABSTRACT

Background: Hepatocellular carcinoma (HCC) is among the most common and lethal cancers worldwide, especially in China.

Methods: We retrospectively analyzed data from patients who were diagnosed and treated HCC between 2002 and 2011 in a large hospital in northwest China and compared the data between periods 2002-2006 (P1) and 2007-2011 (P2).

Results: 2045 patients were included in analysis. The HCC stages at diagnosis according to the Barcelona clinic liver cancer staging system had no significant change. Treatment options of liver transplantation, transcatheter arterial chemoembolization and other therapy decreased while percutaneous local ablation and supportive care increased from P1 to P2. Options of surgical resection and systematic therapy had no significant change. Patient survival rates at 1, 3 and 5 years significantly improved from P1 to P2. The treatments with increasing option trend had a higher magnitude of survival increase and vise versa.

Conclusion: Over the last 10 years, the patient survival had a significant increase which was mainly a result of the optimal therapeutic selections according to disease stages in this center. However, the proportion of patients diagnosed at early stages of HCC remained low and did not increase, a result calling for implementing surveillance system for at risk patients.

Show MeSH
Related in: MedlinePlus